1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 治療タイプ別スニペット
3.2. 患者タイプ別スニペット
3.3. 販売チャネル別スニペット
3.4. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. アトピー性皮膚炎の有病率の上昇
4.1.1.2. 製品開発活動の活発化と規制当局の承認
4.1.2. 阻害要因
4.1.2.1. 患者のアドヒアランスとコンプライアンスへの懸念
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 特許分析
5.5. 規制分析
5.6. SWOT分析
5.7. パイプライン分析
5.8. 疫学分析
5.9. アンメット・ニーズ
6. 治療タイプ別
6.1. はじめに
6.1.1. 治療タイプ別市場規模分析および前年比成長率分析（%） 6.1.2.
6.1.2. 市場魅力度指数（治療タイプ別
6.2. 副腎皮質ステロイド*市場
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.2.3. ヒドロコルチゾン
6.2.4. モメタゾン
6.2.5. ベタメタゾン
6.2.6. プレドニゾン
6.2.7. その他
6.3. 免疫抑制剤
6.3.1. カルシニューリン阻害薬
6.3.1.1. シクロスポリン
6.3.1.2. タクロリムス
6.3.1.3. ピメクロリムス
6.3.1.4. その他
6.3.2. JAK阻害薬
6.3.2.1. アブロシチニブ
6.3.2.2. ウパダシチニブ
6.3.2.3. その他
6.3.3. PDE-4阻害薬
6.3.4. その他
6.4. 生物製剤
6.4.1. デュピルマブ
6.4.2. トラロキヌマブ
6.4.3. その他
6.5. 抗ヒスタミン薬
6.6. その他
7. 患者タイプ別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）、患者タイプ別
7.1.2. 市場魅力度指数（患者タイプ別
7.2. 小児*市場
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 大人
8. 流通チャネル別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
8.1.2. 市場魅力度指数（流通チャネル別
8.2. 病院薬局
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 小売薬局
8.4. オンライン薬局
9. 地域別
9.1. はじめに
9.1.1. 地域別市場規模分析および前年比成長率分析(%)
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. 序論
9.2.2. 主な地域別ダイナミクス
9.2.3. 市場規模分析および前年比成長率分析（％）、治療タイプ別
9.2.4. 市場規模分析およびYoY成長率分析（%）、患者タイプ別
9.2.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.2.6. 市場規模分析および前年比成長率分析（%）, 国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主な地域別動向
9.3.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
9.3.4. 市場規模分析およびYoY成長率分析（%）、患者タイプ別
9.3.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.3.6. 市場規模分析および前年比成長率分析（%）, 国別
9.3.6.1. ドイツ
9.3.6.2. イギリス
9.3.6.3. フランス
9.3.6.4. スペイン
9.3.6.5. イタリア
9.3.6.6. その他のヨーロッパ
9.4. 南米
9.4.1. はじめに
9.4.2. 地域別主要市場
9.4.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
9.4.4. 市場規模分析およびYoY成長率分析（%）、患者タイプ別
9.4.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.4.6. 市場規模分析および前年比成長率分析（%）, 国別
9.4.6.1. ブラジル
9.4.6.2. アルゼンチン
9.4.6.3. その他の南米諸国
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主な地域別ダイナミクス
9.5.3. 市場規模分析およびYoY成長率分析（％）、治療タイプ別
9.5.4. 市場規模分析およびYoY成長率分析（%）、患者タイプ別
9.5.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.5.6. 市場規模分析および前年比成長率分析（%）, 国別
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. その他のアジア太平洋地域
9.6. 中東・アフリカ
9.6.1. 序論
9.6.2. 主な地域別ダイナミクス
9.6.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
9.6.4. 市場規模分析およびYoY成長率分析（%）、患者タイプ別
9.6.5. 市場規模分析および前年比成長率分析（%）, 販売チャネル別
10. 競合情勢
10.1. 競争シナリオ
10.2. 市場ポジショニング／シェア分析
10.3. M&A分析
11. 企業プロフィール
11.1. Pfizer Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Regeneron Pharmaceuticals Inc
11.3. Sanofi S.A
11.4. AbbVie Inc
11.5. Eli Lilly and Company
11.6. Galderma Inc
11.7. LEO Pharma Inc.
11.8. Incyte Corporation
11.9. Arcutis Biotherapeutics, Inc
11.10. Otsuka Pharmaceutical Co., Ltd
リストは網羅的ではありません
12. 付録
12.1. 会社概要とサービス
12.2. お問い合わせ

Overview
The global atopic dermatitis market reached US$ 9.44 billion in 2023 and is expected to reach US$ 25.98 billion by 2031, growing at a CAGR of 13.7% during the forecast period 2024-2031.
Atopic dermatitis, commonly referred to as eczema is a chronic inflammatory skin condition characterized by itchy, red and swollen skin. It’s part of a group of conditions known as the "atopic triad," which also includes allergic rhinitis (hay fever) and asthma. Atopic dermatitis often starts in childhood and may continue into adulthood, though the severity and symptoms can fluctuate over time. Chronic atopic dermatitis can lead to xerosis (dry, scaly skin), skin cracking and even open sores. During "flares," symptoms worsen significantly, while at other times, symptoms may subside or enter remission.

The demand for atopic dermatitis treatments is growing significantly, driven by increasing disease prevalence, especially among children and the need for more effective therapies. For instance, according to the Atopic Dermatitis Atlas Organization, the prevalence of atopic dermatitis is high, affecting up to 20% of children and up to 10% of adults. The burden of disease ranks 15th worldwide for non-fatal diseases and number one for skin diseases, measured in disability-adjusted life years. Therefore, in 2022, atopic dermatitis is considered a common and burdensome skin disease with a complex pathogenesis. The market demand is also fueled by the rise in moderate-to-severe cases, where traditional topical treatments are often insufficient.

Market Dynamics: Drivers & Restraints
Rising prevalence of atopic dermatitis
Atopic dermatitis is a chronic condition that mainly affects the skin of an individual. The condition is usually diagnosed in younger children between 0 to 4 years. The prevalence and incidence of atopic dermatitis is constantly rising and has become a global burden in recent years. For instance, according to the latest global report on Atopic Dermatitis published in 2022, approximately 223 million population across the globe suffer from atopic dermatitis and among these children (1-4 years of age) accounted for 43 million.

According to the National Eczema Association, nearly 9.6 million children (below 18 years of age) in the United States have atopic dermatitis, and approximately one-third of the population has moderate to severe disease. Moreover, nearly 16.5 million adults (above 18 years of age) are diagnosed with the condition, and approximately 40% of the population has moderate to severe disease.
Moreover, several epidemiology studies have reported an increasing trend in the incidence of atopic dermatitis in the near future. With the expanding healthcare industry, the diagnosis and treatment rate is anticipated to increase combined with the rising number of cases propelling the market positively in the forecast period.
For instance, an epidemiology study published in Frontiers in Microbiology Journal among the Chinese population has stated that the prevalence is steadily growing among the 10-19 age group population. With the growing population, this increasing trend may create a huge burden of cases in the future.

Patient adherence and compliance concerns
Patient adherence and compliance are critical concerns in the atopic dermatitis market, as the chronic, relapsing nature of the disease often requires long-term, consistent treatment for symptom management. However, poor adherence is common, particularly due to the time-intensive and sometimes uncomfortable nature of current treatment regimens.
Many patients, especially those with moderate-to-severe atopic dermatitis, are prescribed topical treatments that need multiple daily applications. This can be cumbersome and challenging to maintain consistently, especially if the treatment irritates or feels greasy on the skin. For instance, according to the National Institute of Health (NIH), in dermatological diseases, non-adherence to treatment is problematic and related to negative therapeutic outcomes. About 50% of patients diagnosed with chronic skin diseases were not adherent to the treatments prescribed by their dermatologists.

Segment Analysis
The global atopic dermatitis market is segmented based on treatment type, patient type, distribution channel and region.

Treatment Type:
The corticosteroids segment is expected to dominate the global atopic dermatitis market share
The corticosteroids segment holds a major portion of the atopic dermatitis market share and is expected to continue to hold a significant portion of the market share over the forecast period. Corticosteroids are essential medications for the treatment of atopic dermatitis (AD) and especially so when it comes to the management of flare-ups and inflammation. As anti-inflammatory agents, these drugs markedly alleviate the signs of cutaneous reddening, papules and pus-filled blisters, pruritis and discomfort caused by the AD condition.

Corticosteroids come in a number of formulations: topical creams, ointments, lacquers which come in various ‘strengths’, from low to super potent depending on the weight of the condition. For mild- to moderate-severity cases, low to medium-potency corticosteroid agents are commonly prescribed but for severe exacerbations, higher potency options are given or those thick dense skin areas such as palms and soles.
The administration of these medications decreases the reactivity of certain parts of the immune system and inflammation of the skin, and allows a patient to recover from chronic and acute forms of the disease. For instance, in July of 2024, ZORYVE (roflumilast) cream 0.15% was commercially launched in the United States to treat mild to moderate atopic dermatitis in adults and children aged 6 and upby Arcutis Biotherapeutics, Inc. which is a commercial-stage biotechnology firm dedicated to the development of significant innovations in the field of immuno-dermatology.
ZORYVE is a cream that can be applied once daily to treat afflicted skin without the need for steroids. It acts fast to reduce itching and resolve impacted skin while also helping to control the condition over the long term.

Moreover, some of the factors that need to be considered when selecting a topical corticosteroid include the age of the patient, the area being treated, and rate of absorption. In general, infants may need a less potent preparation for the management of atopic dermatitis flares. In contrast, teenagers may use a medium or a high-level potency drug. Peripheral absorption of these corticosteroids is maximum in thin areas such as the face and perineum and minimal in thicker regions like the palms and soles. Such cases may require mid-potency or high-potency topical drugs for effective management.

The immunosuppressants segment is the fastest-growing segment in the atopic dermatitis market
The immunosuppressants segment is expected to be the fastest-growing segment over the forecast period. Immunosuppressants are emerging as one of the fastest-growing segments in the atopic dermatitis market due to their effectiveness in managing moderate-to-severe cases that do not respond well to traditional treatments. This growth is driven by the need for therapies that target the underlying immune dysfunction in atopic dermatitis, providing more substantial and longer-lasting relief from symptoms.

Immunosuppressants, including JAK inhibitors such as upadacitinib (Rinvoq) and abrocitinib (Cibinqo) are designed to inhibit specific immune pathways associated with atopic dermatitis inflammatory processes. By directly modulating these pathways, these therapies can reduce inflammation, itching and skin lesions more effectively than non-targeted treatments, improving patient outcomes significantly.

North America is expected to hold a significant position in the global atopic dermatitis market
North America region is expected to hold the largest market share over the forecast period. The healthcare system in North America, especially in the USA, is robust with equipped hospitals, research organizations, and dermatology clinics. This system also aids in diagnosis, treatment and management of Atopic Dermatitis thus influencing the growth of the market. The healthcare services offered are of good quality because there are professionals such as dermatologists and allergists available.

The region leads other regions of the world in the adoption and implementation of modern technologies in the health sector. Most of its countries, particularly the United States where attention to R&D is very high, have been able to come up with new therapies and diagnostic technologies for atopic dermatitis.

For instance, in September 2024, Eli Lilly revealed that Ebglyss an IL-13 targeting inhibitor, has been accepted by USFDA for the treatment of moderate to severe atopic dermatitis (AD). The drug has been approved for use by Adults as well as teens with a 12-year-old or older with a minimum body weight of 40kg who have inadequate AD disease control despite the use of topical prescription therapies.
Moreover, in August 2023, to further enhance the effectiveness of ARCTIVA products, the latter also contains the unique patented HYDROSURF technology invented by the company along with active ingredients approved by the FDA. Research and tests show that the fermented components in HYDROSURF reduce the surface tension of different liquids, making them appropriate for use in formulations meant to treat dry skin disorders like dermatitis, eczema, and even flare-ups of psoriasis. Salicylic acid and colloidal oatmeal are used in each of these psoriasis and eczema therapies to address the main symptoms of their respective conditions.

Asia Pacific is growing at the fastest pace in the atopic dermatitis market
The Asia Pacific region is experiencing the fastest growth in the atopic dermatitis market driven by a combination of rising prevalence, increased healthcare spending, improved access to advanced therapies and greater awareness of dermatological health. For instance, according to Sanofi. Anil Raina, General Manager, Sanofi, declared that more public awareness is required for innovative treatments for difficult-to-treat illnesses like atopic dermatitis to know more about the advancements in the management of atopic dermatitis in India which impacts more than 28 million lives.

Competitive Landscape
The major global players in the atopic dermatitis market include Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A, AbbVie Inc, Eli Lilly and Company, Galderma Inc, LEO Pharma Inc., Incyte Corporation, Arcutis Biotherapeutics, Inc, Otsuka Pharmaceutical Co., Ltd and among others.

Emerging Players
The emerging players in the atopic dermatitis market include Almirall, S.A, Aclaris Therapeutics Inc, Kiniksa Pharmaceuticals, Cara Therapeutics, VYNE Therapeutic and among others.

FDA Approvals
 In September 2024, Eli Lilly and Company cleared that the U.S. Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies. EBGLYSS works by targeting eczema inflammation throughout the body that can lead to dry, itchy and irritated skin.
 In April 2024, Dermavant Sciences released that the U.S. Food and Drug Administration (FDA) accepted the company’s Supplemental New Drug Application (sNDA) for VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older. The Prescription Drug User Fee Act (“PDUFA”) action date assigned by the Agency is in Q4 2024.
 In July 2024, Arcutis Biotherapeutics, Inc. cleared that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch and has been specifically developed to be a treatment option for long-term disease control.

Why Purchase the Report?
• To visualize the global atopic dermatitis market segmentation based on treatment type, patient type, distribution channel and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the atopic dermatitis market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global atopic dermatitis market report would provide approximately 62 tables, 53 figures and 197 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Patient Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Atopic Dermatitis
4.1.1.2. Rising Product Development Activities and Regulatory Approvals
4.1.2. Restraints
4.1.2.1. Patient Adherence and Compliance Concerns
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Pipeline Analysis
5.8. Epidemiology Analysis
5.9. Unmet Needs
6. By Treatment Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Corticosteroids*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Hydrocortisone
6.2.4. Mometasone
6.2.5. Betamethasone
6.2.6. Prednisone
6.2.7. Others
6.3. Immunosuppressants
6.3.1. Calcineurin Inhibitors
6.3.1.1. Cyclosporine
6.3.1.2. Tacrolimus
6.3.1.3. Pimecrolimus
6.3.1.4. Others
6.3.2. JAK Inhibitors
6.3.2.1. Abrocitinib
6.3.2.2. Upadacitinib
6.3.2.3. Others
6.3.3. PDE-4 Inhibitors
6.3.4. Others
6.4. Biologics
6.4.1. Dupilumab
6.4.2. Tralokinumab
6.4.3. Others
6.5. Antihistamines
6.6. Others
7. By Patient Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
7.1.2. Market Attractiveness Index, By Patient Type
7.2. Children*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Adults
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Pfizer Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Regeneron Pharmaceuticals Inc
11.3. Sanofi S.A
11.4. AbbVie Inc
11.5. Eli Lilly and Company
11.6. Galderma Inc
11.7. LEO Pharma Inc.
11.8. Incyte Corporation
11.9. Arcutis Biotherapeutics, Inc
11.10. Otsuka Pharmaceutical Co., Ltd
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

❖ 世界のアトピー性皮膚炎市場に関するよくある質問(FAQ) ❖

・アトピー性皮膚炎の世界市場規模は？
→DataM Intelligence社は2023年のアトピー性皮膚炎の世界市場規模を94億4,000万米ドルと推定しています。

・アトピー性皮膚炎の世界市場予測は？
→DataM Intelligence社は2031年のアトピー性皮膚炎の世界市場規模を259億8,000万米ドルと予測しています。

・アトピー性皮膚炎市場の成長率は？
→DataM Intelligence社はアトピー性皮膚炎の世界市場が2024年～2031年に年平均13.7%成長すると予測しています。

・世界のアトピー性皮膚炎市場における主要企業は？
→DataM Intelligence社は「Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A, AbbVie Inc, Eli Lilly and Company, Galderma Inc, LEO Pharma Inc., Incyte Corporation, Arcutis Biotherapeutics, Inc, Otsuka Pharmaceutical Co., Ltdなど ...」をグローバルアトピー性皮膚炎市場の主要企業として認識しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。